Unknown

Dataset Information

0

Lorcaserin vs. Phentermine among non-surgical and surgical obese patients: Anthropometric, glycemic, lipid, safety and cost outcomes.


ABSTRACT:

Background

To evaluate effectiveness, safety, and costs of Lorcaserin vs. phentermine among obese non-surgical and surgical patients (post bariatric surgery).

Methods

This retrospective study retrieved charts of all patients (January 2013-June 2016) who received Lorcaserin or phentermine for 3 months. The study assessed anthropometric, glycemic, and lipid changes, as well as side effects and cost of medications among overweight and obese non-surgical (n = 83) and surgical patients (n = 46). These two patient groups were compared using Chi-square (χ2) and unpaired't' test for qualitative and quantitative variables respectively.

Results

At 3 months, among the non-surgical group, Phentermine patients had greater percentage of total weight loss (TWL%) (7.65 ± 8.26 vs. 2.99 ± 3.72%, P = 0.003), and greater BMI reduction (-3.16 ± 3.63 vs. -1.15 ± 1.53 kg/m2, P = 0.003) than Lorcaserin. Within the surgical group, Lorcaserin patients had significantly smaller TWL% (1.86 ± 5.06 vs. 7.62 ± 9.80%, P = 0.012), and smaller BMI reduction (-0.74 ± 1.80 vs. -3.06 ± 4.08 kg/m2, P = 0.012) than Phentermine. Lorcaserin exhibited significant total cholesterol and LDL improvements only among surgical patients with significant weight reduction (≥5% TW). Both medications were not associated with glycemic improvements among non-surgical and surgical groups. Phentermine had slightly more side effects but was less expensive.

Conclusions

Among both patient groups, phentermine was more effective in achieving weight loss. Lorcaserin showed dyslipidemia improvements only among surgical patients who achieved significant weight reduction. Anti-obesity medications as part of weight management programs can result in weight loss among non-surgical and surgical patients, or halt weight regain among surgical patients. This is the first study to evaluate the effectiveness and safety of two anti-obesity medications (lorcaserin vs. phentermine) among two distinct obese patient groups, non-surgical and surgical patients.

SUBMITTER: Elhag W 

PROVIDER: S-EPMC6677860 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5518190 | biostudies-literature
| S-EPMC5641625 | biostudies-literature
| S-EPMC5788290 | biostudies-literature
| S-EPMC3270297 | biostudies-literature
| S-EPMC6723855 | biostudies-literature
2008-12-01 | GSE10028 | GEO
| S-EPMC7068336 | biostudies-literature
| S-EPMC7407211 | biostudies-literature
2020-09-15 | GSE157569 | GEO
| S-EPMC6459401 | biostudies-literature